Razan Hashem Madi

Ms. Razan Hashem Madi

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2025 in Pharmacia
Verified
Journal Article
Open access
PDF file
AAAhmad Saleh Al-Radaideh
Ahmad Saleh Al-Radaideh
MAmanal A. Abbas
manal A. Abbas
AAAya Y. Al-Kabariti
Aya Y. Al-Kabariti
MAmoath alqaraleh
moath alqaraleh
RMRazan Hashem Madi
Razan Hashem Madi
RORazan Obeidat
Razan Obeidat
Background: The combination of chemotherapeutic agents with natural compounds has gained attention as a strategy to improve treatment effectiveness and reduce adverse effects of cancer therapies. This study investigates the potential use of rhoifolin, a citrus-derived flavonoid, to sensitize triple-negative breast cancer cells (MDA-MB-231) to doxorubicin. Materials and methods: The cytotoxicity of rhoifolin, doxorubicin, and their combination was assessed via MTT assay. Cell migration and proliferation were evaluated through scratch and colony formation assays, respectively. Caspase 3, Bax, and Bcl-2 gene expression were analyzed to explore apoptotic mechanisms. Results: The IC50 values were 6.22 µM for doxorubicin and 102 µM for rhoifolin. Rhoifolin significantly enhanced doxorubicin’s cytotoxic effect with a combination index <1 at various ratios. At a dose of 50 µM rhoifolin, the anti-migratory effect of 1.5 µM doxorubicin was significantly increased (p < 0.01). The combination reduced colony formation to 72.5 ± 8.5 colonies compared to 202 ± 9 in the control group. Moreover, the combination increased caspase 3 gene expression by 22.2-fold. Conclusion: Rhoifolin potentiated the anti-cancer effects of doxorubicin, suggesting its potential as an adjuvant therapy in cancer.

8 April 2026 in South African Journal of Botany
Verified
Journal Article
Open access
HNHamdi Nsairat
Hamdi Nsairat
HAHanan Azzam
Hanan Azzam
ASAlaa Mohammad Sanabrh
Alaa Mohammad Sanabrh
RMRazan Hashem Madi
Razan Hashem Madi
MAMohammed Almullah
Mohammed Almullah
AIAbedalqader Ibrahim
Abedalqader Ibrahim

13 February 2026 in Cancers
Verified
Journal Article
Open access
PDF file
HAHayat Asaad Al-Ali
Hayat Asaad Al-Ali
Mohamed El-TananiMohamed El-Tanani
Mohamed El-Tanani
Shakta Mani SatyamShakta Mani Satyam
Shakta Mani Satyam
TATalal Al-Qaisi
Talal Al-Qaisi
LYLukman Yusuf
Lukman Yusuf
RKRahmeh Khirfan
Rahmeh Khirfan
Background: Cancer progression is driven by coordinated dysregulation of intracellular transport, proteostasis, and extracellular matrix remodeling. Therapeutic strategies targeting a single pathway often fail due to tumor adaptability and resistance. Drug repurposing offers a promising approach to identify multi-target anticancer agents with established safety profiles. Pimozide, an FDA-approved antipsychotic drug, has recently emerged as a candidate with potential anticancer activity, although its molecular mechanisms remain incompletely understood. Objectives: This study aimed to investigate the anticancer effects of pimozide across breast, colorectal, and pancreatic cancer models, with a specific focus on its modulation of Ran GTPase signaling, Skp1–Cullin–F-box (SCF) ubiquitin ligase components, and matrix metalloproteinase-2–mediated extracellular matrix remodeling. Methods: Cell viability was assessed using MTT assays in MDA-MB-231, MCF-7, HT-29, and PanC-1 cell lines. Quantitative real-time polymerase chain reaction was employed to evaluate the expression of Ran, MMP2, Cullin1, Rbx1, SKP2, and FBXW10 following pimozide treatment. Molecular docking and MMGBSA analyses were performed to characterize binding interactions between pimozide and selected target proteins. Results: Pimozide induced concentration-dependent cytotoxicity in all tested cell lines with variable IC50 values. Treatment resulted in consistent downregulation of Ran and MMP-2 across cancer types, alongside context-dependent modulation of SCF complex components. Notably, FBXW10 exhibited the strongest binding affinity to pimozide in silico, suggesting functional disruption of ubiquitin-mediated proteostasis. Conclusions: Pimozide exerts anticancer effects through coordinated disruption of nucleocytoplasmic transport, proteostasis regulation, and matrix remodeling. These findings support the repositioning of pimozide as a multi-target anticancer agent and provide a mechanistic foundation for further translational investigation.

14 January 2026 in Pharmacia
Verified
Journal Article
Open access
PDF file
AAAya Y. Al-Kabariti
Aya Y. Al-Kabariti
MAmanal A. Abbas
manal A. Abbas
MAmoath alqaraleh
moath alqaraleh
RMRazan Hashem Madi
Razan Hashem Madi
YBYasser Bustanji
Yasser Bustanji
NANowar Alsarayreh
Nowar Alsarayreh
Background : Triple-negative breast cancer (TNBC) represents approximately 15% of breast cancer cases worldwide. This subtype is characterized by aggressive behavior, poor prognosis, and a high recurrence rate. The lack of estrogen receptor alpha (ERα) renders hormonal therapies ineffective, leaving chemotherapy as the mainstay of treatment. However, chemotherapy often causes severe side effects. This study investigates the cytotoxic activity of ononin against TNBC in vitro and evaluates its potential to enhance the chemosensitivity of doxorubicin (DOX) in MDA-MB-231 cells. Materials and methods : The effects of ononin and the ononin–DOX combination on cytotoxicity, migration, colony formation, and apoptosis were investigated. Results : Ononin exhibited a cytotoxic effect against MDA-MB-231 cells, with an IC 50 of 50 µM, while DOX had an IC 50 of 1.8 µM. The CompuSyn-calculated combination index (CI) values indicated synergistic interactions, ranging from 0.23 to 0.08 at a constant DOX concentration of 1.8 µM. Analysis of the dose-reduction index (DRI) revealed 6.98-, 16.22-, and 66.86-fold reductions in the effective doses of DOX at ED 50 , ED 75 , and ED 95 , respectively, when combined with a 10-fold concentration of ononin. Combining 0.45 µM DOX with 6 µM ononin resulted in a significant decrease in colony formation compared with 0.45 µM DOX alone (p < 0.0001). Ononin also exhibited anti-migratory activity, and its combination with DOX further reduced cell migration compared with DOX alone after 72 hours (p < 0.05). However, ononin (25 µM) had no significant effect on caspase-3 gene expression. Conclusion : This study is the first to demonstrate that ononin alone inhibits viability, migration, and colony formation in MDA-MB-231 cells and synergistically enhances the cytotoxic activity of DOX. These findings suggest that ononin may serve as a promising adjuvant agent to improve DOX efficacy in TNBC therapy.

13 December 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
OMOmar Markab
Omar Markab
ZLZainab Lafi
Zainab Lafi
NSNaeem Shalan
Naeem Shalan
HDHala I. Al-Daghistani Al- Daghistani
Hala I. Al-Daghistani Al- Daghistani
AFAli Fahadawi
Ali Fahadawi
RMRazan Hashem Madi
Razan Hashem Madi
The interest in natural remedies in modern medicine has revealed potent disease-fighting agents, such asCUR(CUR) and nicotinamide (NIC), known for their antioxidant, anti-inflammatory, and immune-boosting properties. This study explores the antibacterial and antimelanoma potential of a CUR-NIC combination and its liposomal formulation. The antibacterial efficacy was assessed against skin infection-causing bacteria, Staphylococcus aureus, while cytotoxicity and migration assays were conducted on the melanoma B16 cancer cell line. The CUR-NIC combination (1:1) demonstrated an inhibition zone of 18±0.8 mm against S. aureus and a MIC of 31.25 µg/ml, outperforming CUR alone. Whereas Lip-CUR-NIC showed an inhibition zone of 12±0.8 mm against S. aureus and a MIC of 37.5 µg/ml. Notably, the cytotoxicity assay revealed that the CUR-NIC duo synergistically inhibited melanoma cell proliferation (CI<1). Liposomal preparations further enhanced this effect, with Lip-CUR-NIC showing a remarkably low IC50 of 8.5 ± 0.3 µM compared to CUR (IC50= 9.8 ± 2.2 µM) and NIC (IC50=135.95 ± 10.2 µM). These findings highlight the synergistic potential of CUR and NIC, especially in their liposomal form, offering a promising strategy for more effective cancer treatment.

10 July 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Akram Jawad KadhimAkram Jawad Kadhim
Akram Jawad Kadhim
ITIbrahim Deeb Tawfiq²
Ibrahim Deeb Tawfiq²
Mohamed El-TananiMohamed El-Tanani
Mohamed El-Tanani
FMFrezah Muhana¹
Frezah Muhana¹
YEYahia El-Tanani
Yahia El-Tanani
Abdulaziz Rida IbrahimAbdulaziz Rida Ibrahim
Abdulaziz Rida Ibrahim
Background/objectives: Colorectal cancer (CRC) remains a cause of cancer-related mortality worldwide, with therapeutic progress hindered by poor tumor selectivity and acquired drug resistance. This study investigated the anticancer efficacy of simvastatin, administered as a free drug or encapsulated within mesoporous SBA-16 nanoparticles (NPs), against HT-29 colorectal cancer cells in two-dimensional monolayer and three-dimensional spheroid culture models. Methods: SBA-16 NPs achieved drug-loading efficiency of 73.83% and accelerated cumulative release of 91.93% within 30 min, compared to 35.24% for the free drug. Cell viability and proliferation were assessed via MTT and clonogenic assays, while interleukin-6 (IL-6) levels were measured by ELISA to evaluate anti-inflammatory activity. Results: Simvastatin-loaded SBA-16 NPs reduced the IC50 from 27.86 µg/mL to 4.43 µg/mL, representing a 6.29-fold enhancement in cytotoxic potency (p < 0.001), and significantly inhibited colony formation and suppressed IL-6 secretion, indicating modulation of inflammatory pathways implicated in tumor progression. In the 3D spheroid model, the nanoparticle formulation induced dose-dependent inhibition superior to the free drug. Conclusions: These findings demonstrate that SBA-16 nanocarriers substantially amplify simvastatin’s anticancer efficacy through improved drug solubilisation and rapid release kinetics under sink conditions, with possible—but not directly proven—enhanced cellular interaction/internalisation and modulation of tumor-associated inflammatory signaling. Direct uptake, penetration, mechanistic cell-death, normal-cell selectivity, and in vivo studies are warranted to confirm clinical applicability.